Enveric Biosciences Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Enveric Biosciences Inc trades at $1.35 (market cap $5.32M), while Direxion Daily FTSE China Bull 3x Shares trades at $27.88. The key difference: Direxion Daily FTSE China Bull 3x Shares is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | YINN | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $17.40 | $56.62 |
52-Week Low | $1.28 | $21.45 |
Enterprise Value | $408.82K | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $27.85, up 7.28% with strong bullish technical signals from moving averages and oscillators. The ETF benefits from China's tech-focused stimulus and AI infrastructure investments, though key financial ratios remain unavailable for this leveraged product. Recent news highlights China's $295 billion AI buildout plan and strong export growth, creating favorable conditions for Chinese equities exposure.
The outlook remains cautiously optimistic given China's economic stimulus and tech sector momentum, but YINN's 3x leverage amplifies both gains and losses. Key risks include U.S.-China trade tensions and the inherent volatility of leveraged ETFs. Investors should consider this as a tactical trading vehicle rather than long-term holding.
Trailing returns across standard periods
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →